US tax reform legislation signed into law this past December is expected to help spur an increase in biopharma M&A activity in 2018, including the possibility for mega-mergers, possibly even a deal in which one of the big pharma companies absorbs another – a result not seen since the industry-changing events of 2009.
This is among the projections provided in EY's 2018 M&A Firepower Report, issued Jan. 8 to preview the year ahead...








